Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$33.68 - $41.95 $143,914 - $179,252
-4,273 Reduced 18.26%
19,129 $778,000
Q4 2023

Feb 09, 2024

SELL
$33.32 - $42.1 $192,889 - $243,716
-5,789 Reduced 19.83%
23,402 $865,000
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $730,621 - $882,317
20,039 Added 218.96%
29,191 $1.12 Million
Q2 2023

Aug 14, 2023

SELL
$30.28 - $38.74 $405,479 - $518,767
-13,391 Reduced 59.4%
9,152 $330,000
Q1 2023

May 12, 2023

BUY
$32.86 - $55.7 $740,762 - $1.26 Million
22,543 New
22,543 $861,000
Q2 2022

Aug 12, 2022

BUY
$37.35 - $48.3 $781,735 - $1.01 Million
20,930 New
20,930 $921,000
Q1 2020

May 13, 2020

SELL
$13.9 - $21.83 $236,800 - $371,895
-17,036 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$14.93 - $19.53 $254,347 - $332,713
17,036 New
17,036 $302,000
Q3 2019

Nov 14, 2019

SELL
$15.2 - $17.69 $180,439 - $209,997
-11,871 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$14.75 - $17.26 $175,097 - $204,893
11,871 New
11,871 $204,000
Q4 2018

Feb 13, 2019

SELL
$13.33 - $18.66 $144,043 - $201,639
-10,806 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$16.68 - $18.41 $57,195 - $63,127
-3,429 Reduced 24.09%
10,806 $197,000
Q2 2018

Aug 14, 2018

SELL
$16.87 - $20.3 $621,069 - $747,344
-36,815 Reduced 72.12%
14,235 $240,000
Q1 2018

May 14, 2018

BUY
$17.06 - $21.2 $870,912 - $1.08 Million
51,050 New
51,050 $1 Million
Q4 2017

Feb 09, 2018

SELL
$16.75 - $20.8 $178,153 - $221,228
-10,636 Closed
0 $0
Q3 2017

Nov 08, 2017

SELL
$11.76 - $17.4 $31,752 - $46,979
-2,700 Reduced 20.25%
10,636 $185,000
Q2 2017

Aug 17, 2017

BUY
N/A
13,336
13,336 $171,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.